157 related articles for article (PubMed ID: 18790752)
1. N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine.
Bettayeb K; Sallam H; Ferandin Y; Popowycz F; Fournet G; Hassan M; Echalier A; Bernard P; Endicott J; Joseph B; Meijer L
Mol Cancer Ther; 2008 Sep; 7(9):2713-24. PubMed ID: 18790752
[TBL] [Abstract][Full Text] [Related]
2. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases.
Bettayeb K; Oumata N; Echalier A; Ferandin Y; Endicott JA; Galons H; Meijer L
Oncogene; 2008 Oct; 27(44):5797-807. PubMed ID: 18574471
[TBL] [Abstract][Full Text] [Related]
3. Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases.
Bettayeb K; Tirado OM; Marionneau-Lambot S; Ferandin Y; Lozach O; Morris JC; Mateo-Lozano S; Drueckes P; Schächtele C; Kubbutat MH; Liger F; Marquet B; Joseph B; Echalier A; Endicott JA; Notario V; Meijer L
Cancer Res; 2007 Sep; 67(17):8325-34. PubMed ID: 17804748
[TBL] [Abstract][Full Text] [Related]
4. The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway.
Whittaker SR; Walton MI; Garrett MD; Workman P
Cancer Res; 2004 Jan; 64(1):262-72. PubMed ID: 14729633
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Lacrima K; Valentini A; Lambertini C; Taborelli M; Rinaldi A; Zucca E; Catapano C; Cavalli F; Gianella-Borradori A; Maccallum DE; Bertoni F
Ann Oncol; 2005 Jul; 16(7):1169-76. PubMed ID: 15851403
[TBL] [Abstract][Full Text] [Related]
6. CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells.
Delehouzé C; Godl K; Loaëc N; Bruyère C; Desban N; Oumata N; Galons H; Roumeliotis TI; Giannopoulou EG; Grenet J; Twitchell D; Lahti J; Mouchet N; Galibert MD; Garbis SD; Meijer L
Oncogene; 2014 Dec; 33(50):5675-87. PubMed ID: 24317512
[TBL] [Abstract][Full Text] [Related]
7. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
8. Pyrazolo[1,5-a]-1,3,5-triazine as a purine bioisostere: access to potent cyclin-dependent kinase inhibitor (R)-roscovitine analogue.
Popowycz F; Fournet G; Schneider C; Bettayeb K; Ferandin Y; Lamigeon C; Tirado OM; Mateo-Lozano S; Notario V; Colas P; Bernard P; Meijer L; Joseph B
J Med Chem; 2009 Feb; 52(3):655-63. PubMed ID: 19128055
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of 6-pyridylmethylaminopurines as CDK inhibitors.
Wilson SC; Atrash B; Barlow C; Eccles S; Fischer PM; Hayes A; Kelland L; Jackson W; Jarman M; Mirza A; Moreno J; Nutley BP; Raynaud FI; Sheldrake P; Walton M; Westwood R; Whittaker S; Workman P; McDonald E
Bioorg Med Chem; 2011 Nov; 19(22):6949-65. PubMed ID: 21982796
[TBL] [Abstract][Full Text] [Related]
10. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives.
Tang L; Li MH; Cao P; Wang F; Chang WR; Bach S; Reinhardt J; Ferandin Y; Galons H; Wan Y; Gray N; Meijer L; Jiang T; Liang DC
J Biol Chem; 2005 Sep; 280(35):31220-9. PubMed ID: 15985434
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine.
De Azevedo WF; Leclerc S; Meijer L; Havlicek L; Strnad M; Kim SH
Eur J Biochem; 1997 Jan; 243(1-2):518-26. PubMed ID: 9030780
[TBL] [Abstract][Full Text] [Related]
12. Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.
Paprskárová M; Krystof V; Jorda R; Dzubák P; Hajdúch M; Wesierska-Gadek J; Strnad M
J Cell Biochem; 2009 Jun; 107(3):428-37. PubMed ID: 19308936
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P
Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586
[TBL] [Abstract][Full Text] [Related]
14. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma.
Cheng CK; Gustafson WC; Charron E; Houseman BT; Zunder E; Goga A; Gray NS; Pollok B; Oakes SA; James CD; Shokat KM; Weiss WA; Fan QW
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12722-7. PubMed ID: 22802621
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.
Meijer L; Borgne A; Mulner O; Chong JP; Blow JJ; Inagaki N; Inagaki M; Delcros JG; Moulinoux JP
Eur J Biochem; 1997 Jan; 243(1-2):527-36. PubMed ID: 9030781
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of the lethality of the histone deacetylase inhibitor LAQ824 by the cyclin-dependent kinase inhibitor roscovitine in human leukemia cells.
Rosato RR; Almenara JA; Maggio SC; Atadja P; Craig R; Vrana J; Dent P; Grant S
Mol Cancer Ther; 2005 Nov; 4(11):1772-85. PubMed ID: 16275999
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases.
Zatloukal M; Jorda R; Gucký T; Řezníčková E; Voller J; Pospíšil T; Malínková V; Adamcová H; Kryštof V; Strnad M
Eur J Med Chem; 2013 Mar; 61():61-72. PubMed ID: 22770608
[TBL] [Abstract][Full Text] [Related]
18. Roscovitine targets, protein kinases and pyridoxal kinase.
Bach S; Knockaert M; Reinhardt J; Lozach O; Schmitt S; Baratte B; Koken M; Coburn SP; Tang L; Jiang T; Liang DC; Galons H; Dierick JF; Pinna LA; Meggio F; Totzke F; Schächtele C; Lerman AS; Carnero A; Wan Y; Gray N; Meijer L
J Biol Chem; 2005 Sep; 280(35):31208-19. PubMed ID: 15975926
[TBL] [Abstract][Full Text] [Related]
19. The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.
Ferguson M; Luciani MG; Finlan L; Rankin EM; Ibbotson S; Fersht A; Hupp TR
Cell Cycle; 2004 Jan; 3(1):80-9. PubMed ID: 14657672
[TBL] [Abstract][Full Text] [Related]
20. (R)-roscovitine (CYC202, Seliciclib) sensitizes SH-SY5Y neuroblastoma cells to nutlin-3-induced apoptosis.
Ribas J; Boix J; Meijer L
Exp Cell Res; 2006 Jul; 312(12):2394-400. PubMed ID: 16765943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
